S&P 500
(0.80%) 5 168.86 points
Dow Jones
(0.26%) 38 776 points
Nasdaq
(0.93%) 16 306 points
Oil
(0.56%) $78.55
Gas
(2.43%) $2.19
Gold
(1.11%) $2 334.20
Silver
(3.65%) $27.66
Platinum
(-0.04%) $964.95
USD/EUR
(-0.01%) $0.929
USD/NOK
(-0.38%) $10.83
USD/GBP
(-0.10%) $0.796
USD/RUB
(-0.12%) $91.35

Actualizaciones en tiempo real para Axsome Therapeutics Inc [AXSM]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-06)

Expected move: +/- 11.34%

BUY
59.57%
return -1.14%
SELL
25.53%
return 20.89%
Última actualización6 may 2024 @ 15:43

1.34% $ 75.81

COMPRAR 302 min ago

@ $74.81

Emitido: 6 may 2024 @ 10:40


Retorno: 1.33%


Señal anterior: may 3 - 15:47


Señal anterior: Vender


Retorno: -0.55 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 15:43):
Our systems believe the stock currently is undervalued by 0.96% compare to its pairs and should correct upwards.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...

Stats
Volumen de hoy 685 428
Volumen promedio 723 995
Capitalización de mercado 3.59B
EPS $0 ( 2024-02-20 )
Próxima fecha de ganancias ( $-1.200 ) 2024-06-07
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -14.38
ATR14 $4.67 (6.16%)
Insider Trading
Date Person Action Amount type
2024-04-01 Jacobson Mark L. Buy 24 662 Common Stock
2024-04-01 Jacobson Mark L. Sell 24 662 Stock Option (Right to Buy)
2024-04-01 Jacobson Mark L. Sell 24 662 Common Stock
2024-03-14 Jeffs Roger Buy 16 976 Common Stock
2024-03-14 Jeffs Roger Buy 13 000 Common Stock
INSIDER POWER
55.25
Last 99 transactions
Buy: 2 269 939 | Sell: 680 650
Correlación (AI algo v.1.1b): Undervalued: 0.96% $76.54 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.85 (strong negative)
Corto: 0.87 (strong)
Signal:(58) Same movement expected

Axsome Therapeutics Inc Correlación

10 Correlaciones Más Positivas
MMAC0.888
AMGN0.885
BOCH0.879
PDCO0.878
MIRM0.876
RNEM0.87
BATRA0.869
SINO0.866
BATRK0.86
VIRI0.858
10 Correlaciones Más Negativas
APOP-0.937
TDAC-0.893
MAGS-0.891
CMLF-0.868
BHTG-0.861
VTRU-0.848
GAINL-0.847
TRIT-0.845
RMRM-0.843
XOG-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Axsome Therapeutics Inc Correlación - Moneda/Commodity

The country flag -0.32
( neutral )
The country flag -0.59
( weak negative )
The country flag 0.29
( neutral )
The country flag 0.25
( neutral )
The country flag 0.48
( neutral )
The country flag -0.65
( moderate negative )

Axsome Therapeutics Inc Finanzas

Annual 2023
Ingresos: $270.60M
Beneficio Bruto: $237.70M (87.84 %)
EPS: $-5.27
FY 2023
Ingresos: $270.60M
Beneficio Bruto: $237.70M (87.84 %)
EPS: $-5.27
FY 2022
Ingresos: $50.04M
Beneficio Bruto: $44.84M (89.61 %)
EPS: $-4.86
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-3.47

Financial Reports:

No articles found.

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico